Seres Therapeutics reports FY 2025 net income of $5.7M from continuing ops; cash runway through Q3 2026

Seres Therapeutics, Inc.

Full-year 2025 net income from continuing ops $5.7M vs net loss of $125.8M in 2024; Q4 net loss $15.3M.
Cash and equivalents $45.8M as of Dec 31, 2025; expects to fund operations through Q3 2026.
SER-155 IST for immune checkpoint-related enterocolitis fully enrolled; data expected Q2 2026.
SER-603 for IBD in IND-enabling activities; seeking partnerships for clinical advancement.
Richard Kender appointed Executive Chair and interim CEO; company prioritized inflammatory/immune programs.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Seres Therapeutics, Inc. reported the fourth quarter of 2025 results: net income Net loss from continuing operations was $15.3 million.

Period: the fourth quarter of 2025
Net income: Net loss from continuing operations was $15.3 million
Result: reported results

Exact text from the filing

Net loss from continuing operations was $15.3 million for the fourth quarter of 2025, as compared to a net loss from continuing operations of $15.7 million for the same period in 2024.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Seres Therapeutics, Inc. reported the full year 2025 results: net income Net income from continuing operations was $5.7 million.

Period: the full year 2025
Net income: Net income from continuing operations was $5.7 million
Result: reported results

Exact text from the filing

Net income from continuing operations was $5.7 million for the full year 2025, as compared to a net loss from continuing operations of $125.8 million for 2024.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Seres Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-103034

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.